acute myeloid leukemia
Conditions
Interventions
Group A:Low dose chemotherapy
Group B:HMA
Group C:HMA combination of HMA with low-dose chemotherapy
Sponsors
Shanghai 6th people's Hospital affiliated to Shanghai Jiaotong University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The newly diagnosed elderly patients with AML confirmed by bone marrow morphology and immunology, including those with denove MDS and MDS/MPN subtypes, were evaluated by the above criteria and the initial diagnosis progressed to AML; 2. Aged at least 60 years; 3. Obtain informed consent signed by the patient or family member.
Exclusion criteria
Exclusion criteria: 1. APL patients; 2. Leukemia Immunology Integral System (EGIL, 1998). AML with lymphatic antigen expression (Ly + AML, but lymphatic score < 2); 3. Recurrent and retreated patients, but excluding precursor MDS, MDS/MPN treatment history; 4. Exclusion of AML extramedullary infiltration and myelosarcoma; 5. Allergies or obvious taboos to any drug involved in the program; 6. Failure to understand or comply with research programs; 7. History of intolerance or allergy to similar drugs; 8. Any other obstacles to research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission;overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| early mortality rate; | — |
Countries
China
Contacts
Public ContactChang chunkang
Shanghai 6th people's Hospital affiliated to Shanghai Jiaotong University
Outcome results
None listed